Systematic review / meta-analysis / 2009
Evidence that Ginkgo biloba provides predictable, clinically significant benefits for dementia or cognitive impairment is inconsistent and unreliable.
A systematic review assessed 36 randomized, double-blind trials comparing Ginkgo biloba extracts to placebo in people with acquired cognitive impairment or dementia. Most trials were small and lasted less than 3 months, while nine 6-month trials included 2,016 patients. Results from more recent trials were inconsistent across cognition, daily activities, mood, depression, and carer burden; three of the four most recent trials found no difference versus placebo, while one reported large treatment effects. No significant differences were seen in adverse events, and a subgroup of 925 Alzheimer's patients showed no consistent benefit.
- Study type
- Systematic review and meta-analysis of randomized controlled trials
- Who was studied
- People with acquired cognitive impairment or dementia across 36 trials (9 trials of 6 months had 2,016 patients; Alzheimer's subgroup had 925 patients)
- What was measured
- Cognition, activities of daily living, mood, depression, carer burden, and adverse events
THE PAPER
Ginkgo biloba for cognitive impairment and dementia.
Birks J, Grimley Evans J. Cochrane Database Syst Rev, 2009.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.